SAB Biotherapeutics (SABS) Non-cash Items (2021 - 2026)

SAB Biotherapeutics has reported Non-cash Items for 6 years, with the latest figure at $27.6 million in Q1 2026.

• For the quarter ending Q1 2026, Non-cash Items rose 383.44% year-over-year to $27.6 million; the trailing twelve-month figure through Mar 2026 stood at $27.6 million (up 383.44% YoY), and the FY2025 full-year result was $26.1 million, up 2098.01% from the prior year.
• Non-cash Items for Q1 2026 stood at $27.6 million, up from $26.1 million in the prior quarter.
• The five-year high for Non-cash Items was $27.6 million in Q1 2026, with the low at $8500.0 in Q3 2025.
• Historically, Non-cash Items has averaged $6.1 million across 5 years, with a median of $2.9 million in 2022.
• Annual changes were most pronounced in 2022 — Non-cash Items slumped 98.33% — and 2025, when it surged 2098.01%.
• SAB Biotherapeutics' Non-cash Items stood at $109891.0 in 2022, then surged by 505.12% to $664967.0 in 2023, then soared by 78.36% to $1.2 million in 2024, then surged by 2098.01% to $26.1 million in 2025, then gained by 5.7% to $27.6 million in 2026.
• The last three Non-cash Items figures came in at $27.6 million (Q1 2026), $26.1 million (Q4 2025), and $8500.0 (Q3 2025), per Business Quant data.